ライフサイエンスコーパス: arm

1 290 adolescents were enrolled (41 or 42 per arm).

2 atients were included (100 in each treatment arm).

3 cribe as antibody RING-mediated destruction (ARMeD).

4 red comprehensively for all portions of each arm.

5 ention and 106 (95%, 106/112) in the control arm.

6 ol group and 19 (86%) in the investigational arm.

7 150% and 40% stronger than in the girls-only arm.

8 e events (AEs) in the SD arm and 9 in the HD arm.

9 was unassociated with changes in the control arm.

10 avenously in a peripheral vessel in the left arm.

11 the control arm and 136 in the intervention arm.

12 tion group and 23 patients to the delayed-GS arm.

13 hogens between controls and any intervention arm.

14 prasugrel or ticagrelor prescribing in each arm.

15 compared to children in the standard message arm.

16 within 6 months of random allocation in each arm.

17 e lenalidomide arm and 90 to the observation arm.

18 the ICD arm and 135 patients to the control arm.

19 I, 0.27 to 0.90), were observed in the BMDex arm.

20 equency of syncope (9.2%) in the OH+ placebo arm.

21 independent evaluator before and after each arm.

22 en, and dentists were not blind to allocated arm.

23 eristics were well matched between treatment arms.

24 1%, respectively, with no difference between arms.

25 raft survival were not different between the arms.

26 new MA (P = 0.997) were evident among study arms.

27 ompares the distribution of rankings between arms.

28 ximal centromeres and the core of chromosome arms.

29 ing were not significantly different between arms.

30 cteristics were balanced across intervention arms.

31 significantly different among the treatment arms.

32 e in the proportion of AEs between treatment arms.

33 ly assigned 1:1 to concurrent versus delayed arms.

34 on symptoms in the sertraline versus placebo arms.

35 re higher in the PCI (5.7%) and CABG (16.5%) arms.

36 rs subsequently preferentially lose multiple arms.

37 aracteristics were similar between treatment arms.

38 CIs were not significantly different between arms.

39 which LNS were compared with passive control arms.

40 ere 59.6% and 30.7%, respectively, in the SD arms.

41 ate (TDF) and dolutegravir/emtricitabine/TDF arms.

42 TXM was reduced by 35% in both experimental arms.

43 d (difference in number compared to non-WASH arms, -0.07 [95% confidence interval, -.14 to -.02]), bu

44 26, DHEA levels remained higher in the LPV/r arm: 0.45 versus 0.13 ng/mL (P = .002).

45 ith completion of protocol treatment in 68% (arm 1) v 54% (arm 2).

46 patients started their allocated treatment (arm 1, 543; arm 2, 525), with completion of protocol tre

47 rent, with 76.5% (95% CI, 72.7% to 79.9%) in arm 1, which is higher than anticipated, and 75.8% (95%

48 1.02) and OS of 73.5% v 73.7% (HR, 1.19) in arms 1 and 2, respectively.

49 antibody in a peripheral vessel in the right arm (10 mg/kg, providing therapeutic-level antibody conc

50 In the intervention arm, 1354 patients received prebiotic or symbiotic prepa

51 of protocol treatment in 68% (arm 1) v 54% (arm 2).

52 arted their allocated treatment (arm 1, 543; arm 2, 525), with completion of protocol treatment in 68

53 pated, and 75.8% (95% CI, 71.9% to 79.3%) in arm 2.

54 pant was higher in intervention than control arm (2.65 versus 1.31; SMD 0.64; 95% CI 0.36-0.92; P < 0

55 ; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03).

56 In the RC arm, 20 (80.0%) participants received cystectomy, includ

57 1, 0.97) and the mHealth with no home visits arm (32% vs. 45%, OR: 0.54, 95% CI: 0.31, 0.96) compared

58 ted in both the mHealth with two home visits arm (33% vs. 45%, Odds Ratio(OR): 0.55, 95% CI: 0.31, 0.

59 57) was significantly higher than in the SOC arm (34%, 18/53; P < .001; relative risk [RR] 2.48, 95%

60 to vaccination were similar between vaccine arms (3AV vs 1AV) after the first (30% vs 18.8%, p = 0.1

61 accine (HD-SD arm) or two SD vaccines (SD-SD arm), 4 weeks apart.

62 rials to assign more patients to an inferior arm, (4) difficulty of validly analyzing results, and (5

63 r sTXB2 (ng/mL) compared with the once-daily arm: 4 (2.1-6.7; n = 79), 2.5 (1.4-5.65, n = 79), and 19

64 ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control a

65 the primary care arm, compared to in the SOC arm (49% [28/57] and 30% [16/53], respectively; P = .043

66 In the standard TTS arm 5 patients (4.3%) died within 90 days of surgery, co

67 central review, versus the chemotherapy TPC arm (5.7 vs 4.2 months; HR = 0.53 [95% CI: 0.29-0.97]),

68 est improvement was observed in the fish oil arm [5.9 (4.8, 7.0) to 5.2 (3.7, 6.8), P = 0.39].

69 II-IV adverse events were equivalent between arms (62.2%).

70 nts commencing treatment in the primary care arm (75%, 43/57) was significantly higher than in the SO

71 scents were randomly assigned to 7 treatment arms: 8, 16, or 24 mg of moxidectin monotherapy; 8, 16,

72 of ELP1 owing to somatic loss of chromosome arm 9q.

73 Twelve patients (14%) were allocated to arm A and discontinued nivolumab, of whom five (42%; 90%

74 hs discontinued nivolumab and were observed (arm A).

75 CI:96.7-99.8) and 98.1% (95%CI:88.2-94.8) in Arm A, and 89.6% (95%CI:85.4-93.0) and 98.5% (95%CI:96.3

76 on of the reproductive hyphae into spores by arming a novel anti-sigma (RsiG) to bind and sequester a

77 Infants were randomized into 4 arms: (A) fIPV, 0.1 mL im; (B) fIPV, 0.2 mL im; (C) fIPV

78 Asian patients in the olaparib arm achieved longer median progression-free survival, as

79 st-year experience of physical (couples' UBL arm adjusted odds ratio [AOR] = 1.00, 95% confidence int

80 nts received nivolumab alone with subsequent arm allocation based on response.

81 The etoposide plus ART arm also closed due to inferiority in March, 2016, follo

82 irty-one patients were randomized to the ICD arm and 135 patients to the control arm.

83 ention-to-treat analysis: 157 in the control arm and 136 in the intervention arm.

84 31/33 were significant in the gender-neutral arm and 150% and 40% stronger than in the girls-only arm

85 s (interquartile range 13-50) in the placebo arm and 34 days (interquartile range 17-62) in the cipro

86 for HCV; 96% received test results in the RT arm and 42% in the LBT arm (odds ratio, 28.72; 95% confi

87 symptoms was 79.0 hours for the oseltamivir arm and 84.0 hours for the placebo arm (P =; .34) in tho

88 ere 3 grade 5 adverse events (AEs) in the SD arm and 9 in the HD arm.

89 mly assigned-92 patients to the lenalidomide arm and 90 to the observation arm.

90 ificant interaction effect between treatment arm and investigated characteristics was demonstrated.

91 y period, 3 participants in the intervention arm and none in the control arm tested HIV positive, and

92 e the exceptional flexibility of the octopus arm and provide a basis for investigating motor control

93 ometrical constraints that change its moment arms and lead to complex posture-dependent variation in

94 he posture dependent muscle geometry, moment arms and lengths of modeled muscles were captured using

95 require localization first to the chromosome arms and then centromeres in mitosis and subsequently th

96 , percentage body fat (PBF), and waist, hip, arm, and thigh circumferences were measured 6-12 months

97 .15, 95% CI: 0.89-1.50; p = 0.291; men's UBL arm AOR = 0.80, 95% CI: 0.63-1.01, p = 0.062).

98 1.28, p = 0.865) or sexual IPV (couples' UBL arm AOR = 0.86, 95% CI: 0.62-1.20, p = 0.378; women's UB

99 1.11, 95% CI 0.87-1.42, p = 0.414; men's UBL arm AOR = 1.02, 95% CI: 0.81-1.28, p = 0.865) or sexual

100 rval [CI]: 0.77-1.30, p = 0.973; women's UBL arm AOR = 1.11, 95% CI 0.87-1.42, p = 0.414; men's UBL a

101 6, 95% CI: 0.62-1.20, p = 0.378; women's UBL arm AOR = 1.15, 95% CI: 0.89-1.50; p = 0.291; men's UBL

102 The 2-year OS rates in the control arm are similar to the PACIFIC trial.

103 ade for each targeted metal) and one acetate arm arranged in a dissymmetrical manner, have been synth

104 The robot arm autonomously aligned with the planned screw trajecto

105 reduced dosing/treatment discontinuation in arm B vs arm C.

106 CI:85.4-93.0) and 98.5% (95%CI:96.3-99.6) in Arm B.

107 g cohort were randomized to either VEN + BR (arm B; VEN 800 mg/d for 1 year + 6 cycles of BR [B 90 mg

108 In the experimental arm, background use of a P2Y(12) inhibitor included clop

109 ) while three male monkeys performed a three-armed bandit learning task.

110 68 electrodes) while monkeys performed a two-armed bandit reinforcement learning task.

111 male participants performed a restless four-armed bandit task in a within-subjects design under thre

112 e performance, and with low errors in moment arms (below 5%) and lengths (below 0.4%).

113 and 375,984 Icelandic samples (MAF = 0.03%, arm BMD P-value = 0.12, forearm fracture P-value = 0.005

114 LDL cholesterol changes in the intervention arm but was unassociated with changes in the control arm

115 nd R 375 mg/m2 on day 1]) or 6 cycles of BR (arm C).

116 dosing/treatment discontinuation in arm B vs arm C.

117 Patients treated with the best-performing arm, C-MTX plus nelarabine, had a 5-year DFS of 91% (n =

118 ticity work using precision neuroimaging and arm casting to unmask previously unknown pulses of spont

119 st market growth, attention of developers to ARM chipsets and Android/iOS is warranted, as well as in

120 Midupper arm circumference (MUAC) is used as an independent diagn

121 We implemented a multi-arm, cluster-randomised community effectiveness trial in

122 Our two-arm, cluster-randomised controlled trial was done in sex

123 ry (CRi) was significantly reduced in the GO arm compared with the standard arm (P = .005), with no d

124 erapy (DOT) was shorter in both intervention arms compared to historical (6d each vs 7d; P=0.011).

125 was significantly higher in the primary care arm, compared to in the SOC arm (49% [28/57] and 30% [16

126 In such cases, the presence of armed conflict may ultimately prevent incursions to a gr

127 ates in the immediate EVR versus delayed EVR arm, considering the worst- and best-case scenario appro

128 >rho kinase (ROCK) pathway in MBn suppresses ARM consolidation, allowing the formation of PSD-LTM.

129 frequency of whole chromosome or chromosome arm copy number alterations and were associated with an

130 of this renin-angiotensin system protective arm could influence long-term outcomes in patients with

131 Five participants in the intervention arm could not complete the trial because of hypotension.

132 s performed against a commercially available arm cuff device yielding systolic and diastolic readings

133 One subject in the investigational arm died with functioning pancreas and kidney grafts.

134 stage showed no difference between treatment arms during double-blind treatment, but during the open-

135 e functionally monovalent as a result of Fab-arm exchange.

136 ECEPT was a prospective, multicenter, single-arm Food and Drug Administration-regulated investigation

137 action between PD-L1 CPS >= 10 and treatment arm for progression-free survival or overall survival.

138 nificantly different between the 3 adherence arms for plasma (P < .0001) and urine (P = .0002).

139 mpare the outcomes among different treatment arms for the primary outcomes.

140 We conducted a retrospective study of 531 VA-Armed Forces coccidioidomycosis patients diagnosed betwe

141 Armed forces often rely on strict hierarchical organizat

142 84/93 (90.3%) participants in the DTG + FTC arm had an HIV-1 RNA viral load of <50 copies/ml compare

143 The two treatment arms had similar response (HR = 1.08, 95% CI (0.76, 1.52

144 s technology, we identified which chromosome arm harbors the virus genome and obtained a high-resolut

145 or death was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P <

146 90.9% in the RA arm versus 83.7% in the RITA arm (hazard ratio for mortality, 0.53 [95% CI, 0.30-0.95

147 ition (RAP and thus g-gradient) during short-arm human centrifugation (SAHC) upon cardiovascular resp

148 The treatment arms included (1) topical natamycin 5% alone, (2) topica

149 The formation of ARM inhibits PSD-LTM but the underlying molecular proces

150 log-rank test) and enlargement rates (time x arm interaction test).

151 due to the difference in HIVST between the 2 arms (intervention 1.41 versus control 0.36; SMD 0.75; 9

152 This single-arm, interventional trial took place at the Johns Hopkin

153 The octopus arm is often referred to as one of the most flexible lim

154 ed at the four most common sites (left upper arm, left wrist, right upper arm, right wrist) had adequ

155 d found the presence of hexagonal nets whose arm lengths were similar to those of the hexagonal nets

156 nced greater improvements than the C + Ex in arm LM (0.07 kg; 95% CI: 0.01, 0.14; P = 0.029), gait sp

157 than among those in the edaravone-edaravone arm (log-rank test, p<0.001).

158 Control and treatment arm loss to follow-up and withdrawal were 24% and 23%, r

159 weeks = 7) and 21% in the standard protocol arm (mean gestational weeks = 6).

160 eous abortion was reported by 21% in the HPT arm (mean gestational weeks = 7) and 21% in the standard

161 We found that a whole-arm model, unlike classic models, successfully predicted

162 Thus, the pattern generator for dexterous arm movement is distributed across multiple, strongly in

163 In this multi-arm, multicentre, open-label, phase 1b study, we enrolle

164 This single-arm, multicentre, phase 2 trial was done in 19 European

165 In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients ag

166 rm (n = 598; 83%) than the standard protocol arm (n = 535 (69%); mean difference = 15%, 95% CI: 10, 1

167 ention (>=1 follow-up) was higher in the HPT arm (n = 598; 83%) than the standard protocol arm (n = 5

168 roup, double-blind RCT and randomized into 4 arms (n = 23): HP-diet and beta-cryptoxanthin (hypocalor

169 that NSPs play no role in either NETosis or arming NETs with proteolytic activity.

170 This was an open-label, two-arm, non-inferiority, multi-center, randomized controlle

171 est results in the RT arm and 42% in the LBT arm (odds ratio, 28.72; 95% confidence interval, 10.27-8

172 en globally with no difference between study arms [odds ratio (OR) 0.96 (0.74-1.25)].

173 n the mEndoG structure accommodates a second arm of a junction.

174 ng penicillin allergy de-labeling into a new arm of antimicrobial stewardship programs (ASPs) has bec

175 y and pathogenic variants affecting the long arm of chromosome 22 (22q) result in meningiomas in neur

176 survive in an ocean of microbes without one arm of the adaptive immune defense suggests a high degre

177 A allowing the nuclease domain to incise one arm of the fork.

178 tion and selection during development of one arm of the mammalian adaptive immune response.

179 g light from either the same or the opposite arm of the maze.

180 In RAPCO-SV (the SV versus RA arm of the RAPCO trial), 225 patients >=70 years of age

181 circadian rhythm by stabilizing the negative arm of the transcription/translation feedback loop witho

182 The retrospective arm of this study included 146 patients with histologica

183 NB_ARC contigs showed identity with the long arm of wheat chromosome 6B confirming the introgression

184 lar or complementary nucleobases on opposite arms of a chiral polyhydroxypyrrolidine while also ensur

185 igen-antibody structure in which the two Fab arms of a single antibody occupy the two arm regions of

186 The neoadjuvant or concurrent ADT arms of both trials were combined into the neoadjuvant g

187 that the proposed strategy allowed the side arms of H(1)/H(2) to be sealed into the RNA sequence-pro

188 s is known about the importance of these two arms of the defence for the ecology and evolution of pro

189 insight into the interplay between different arms of the immune system and the role of ectoparasites

190 lhe40 in the circulating and tissue-resident arms of the immune system, with emphasis on recent work

191 Together, inhibition of these two arms of the neutrophil response likely contributes to th

192 er retainer' and activatory 'stumpy inducer' arms of the QS control pathway.

193 Stretching was matched to exercise dosing arms on the basis of location, frequency, duration, and

194 nths and their mothers were surveyed in each arm, one before the intervention in 2014 (control: n = 1

195 Here we report the results of a single-arm open-label phase I clinical trial designed to determ

196 This was a 24-week, single-arm, open-label study in treatment-experienced adults li

197 In this single-arm, open-label, phase 2 basket trial, we recruited pati

198 The most common adverse events were neck or arm or shoulder pain, arm paraesthesia, dysphagia, and w

199 ollowed by standard dose (SD) vaccine (HD-SD arm) or two SD vaccines (SD-SD arm), 4 weeks apart.

200 of death was reduced by 42% in the tucatinib arm (OS HR, 0.58; 95% CI, 0.40 to 0.85; P = .005).

201 , fluctuations in procedures in the standard arm over the course of the study, high fidelity to the t

202 ced in the GO arm compared with the standard arm (P = .005), with no difference in the cumulative inc

203 ed to 4 patients (3.8%) in the prolonged TTS arm (P = 1.0).

204 eltamivir arm and 84.0 hours for the placebo arm (P =; .34) in those with confirmed influenza infecti

205 se events were neck or arm or shoulder pain, arm paraesthesia, dysphagia, and worsening of myelopathy

206 itive, and 8 sexual partners of intervention arm participants also tested positive.

207 and 3 early, late, and sequential treatment arm patients, respectively.

208 ithin this series blocked binding of the Tat-ARM peptide to TAR in solution assays, whereas its linea

209 an open-label, randomized, multicenter, two-arm phase II trial to investigate cisplatin and gemcitab

210 In this multicentre, open-label, single-arm, phase 2 study (L-MIND), patients older than 18 year

211 We did a multicentre, single-arm, phase 2 trial at eight cancer centres in the USA.

212 This was a single-arm, phase 2 trial done at the MD Anderson Cancer Center

213 This open-label, multicentre, single-arm, phase 2 trial was done at three hospitals in the US

214 In this open-label, single-arm, phase 3 trial, participants were recruited from 24

215 lied the workflow to characterize a 40 kDa 8-arm polyethylene glycol (PEG) functionalized with a male

216 ly, S217A enhanced the maximum rate of lever arm priming (recovery stroke) while slowing ATP hydrolys

217 This open-label, single-arm, prospective cohort trial is the first phase 3 safet

218 ivo These studies highlight an ever-evolving arms race between antiviral factors and viral pathogens

219 The co-evolutionary arms race between predators and their prey has led to co

220 unter evolving bacterial host defenses; such arms race dynamics should lead to divergence between pha

221 lective pressure suggesting a coevolutionary arms race that shapes both ectoparasites and vertebrate

222 In the incessant host-parasite arms race, viruses evolved multiple anti-defense mechani

223 es to gain an advantage in this evolutionary arms race.

224 ces involving multiple traits, we found that arms races can promote diversification when trade-off co

225 In contrast, modelling arms races involving multiple traits, we found that arms

226 contrast, have been engaged in evolutionary arms races with their predators for more than 100 millio

227 parallel-group, multicentre, open-label, two-arm, randomised superiority trial included adults (aged

228 Two-arm RCTs were reviewed to see if sample size estimation

229 The experimental arm received adjuvant cetuximab.

230 ations, whereas 1369 patients in the control arm received placebo or standard care.

231 combined into the neoadjuvant group, and the arms receiving adjuvant ADT were combined into the adjuv

232 Although both arms reduced average grams of alcohol consumed per week

233 Fab arms of a single antibody occupy the two arm regions of the prodomain in the pro- and latent myos

234 In that study, injury to an arm (removal of the tip with a scalpel) 6 hours prior le

235 Here we identify a critical Arm repeat (AR) required for binding Klp64D and Wg signa

236 y transcranial magnetic stimulation over the arm representation of the primary motor cortex, maximal

237 ts in the SD arm v 12.1% and 17.4% in the HD arm, respectively (P = .0005 and < .0001).

238 versus 89%, 76%, and 66% for the observation arm, respectively.

239 rates were 75% and 63% in the Gef+C and Gef arms, respectively (P = .01).

240 ing key pharmacophoric residues in one dimer arm retaining high antagonist affinity.

241 tes (left upper arm, left wrist, right upper arm, right wrist) had adequate correlation coefficients

242 afety and biomarker analysis from the single-arm safety run-in (part 1; n = 9) and biomarker (part 2;

243 acilitate the analysis and interpretation of arm selection events.

244 uated annually using the Disabilities of the Arm, Shoulder, and Hand; Carroll; Hand Transplantation S

245 Along arms, sister chromatids are less precisely aligned, with

246 is driven by a reward-dependent increase in arm stiffness.

247 ient information for the resolution of outer arm structure motifs with recognized biological function

248 As two-arm studies with gene expression profiling have been rar

249 n profiling have been rarer than similar one-arm studies, the methodology for constructing and optimi

250 PersAFOne is a single-arm study evaluating biphasic, bipolar PFA using a multi

251 This was a prospective, single-arm study in which patients 18 to 65 years of age who co

252 lacking, we conducted an open-label, single-arm study to determine the impact of the broad mTOR inhi

253 aim of this prospective, multicenter, single-arm study was to evaluate the feasibility and initial sa

254 EAY131-H is an open-label, single-arm study.

255 MeO cap substituents and beta-Me, Et, or Ph arm substituents are obtained, and a modified condensati

256 expression originating from at least seven q-arm subtelomeres, and at higher levels in mouse pluripot

257 Conventional prosthetic arms suffer from poor controllability and lack of sensor

258 here found to be occluded by a "restraining arm" suggesting a self-inhibition mechanism.

259 all RNAs-including species-specific microRNA arm switching-providing differential gene regulation is

260 t by 2 or more points on the Action Research Arm Test (ARAT) subtest 2 at 3 months after implantation

261 the intervention arm and none in the control arm tested HIV positive, and 8 sexual partners of interv

262 oted among patients in the placebo-edaravone arm than among those in the edaravone-edaravone arm (log

263 While cure rates were >95% in both treatment arms, the Pfkelch13 R561H mutation was identified in 19

264 This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Can

265 Disruption of the NAD(+)-binding site or the ARM-TIR interaction caused constitutive activation of SA

266 r vial with a drain port, and an autosampler arm to deliver liquid extract aliquots at defined time p

267 Although activated NK cells are armed to combat tumors, the tumor microenvironment (TME)

268 ced a large decrease in both the noninvasive arm-to-leg blood pressure gradient (41.2+/-18.7 to 5.6+/

269 DOLPHIN was a phase 1/2, single-arm trial done at The Aurum Institute (Tembisa Clinical

270 ospective, open-label, observational, single-arm trial of 1200 patients across 104 centers within the

271 A single-arm, two-stage design was used.

272 t-diagnosed pharyngeal gonorrhea in a single-arm, unblinded clinical trial.

273 Here, we report that octopus arms use a family of cephalopod-specific chemotactile re

274 urred in 3.2% and 5.0% of patients in the SD arm v 12.1% and 17.4% in the HD arm, respectively (P = .

275 atient survival estimate was 90.9% in the RA arm versus 83.7% in the RITA arm (hazard ratio for morta

276 l was 98%, 93%, and 91% for the lenalidomide arm versus 89%, 76%, and 66% for the observation arm, re

277 mumab/anti-programmed death 1 use in the HDI arm versus ipi3 and ipi10 (P <= .001).

278 was defined as a >= 10% relative increase in arm volume arising > 3 months postoperatively.

279 A custom robotic arm was integrated into a hybrid operating room (OR) equ

280 The treatment-assignment rate to treatment arms was assessed.

281 rates of RNFLT change in the UKGTS treatment arms was enhanced and RNFLT change became a stronger pre

282 ne, imbalance in MA rates across ranibizumab arms was evident (0.5 mg monthly, 19.1%; 0.5 mg PRN, 16.

283 ifference in decline between the 2 treatment arms was not significant (P = .09).

284 Seroconversion after 2 IPV doses in each arm were as follows: (A) 97.3% (90.6-99.7), 98.7% (92.7-

285 reath shields attached to the objective lens arm were better barriers than those of comparable size h

286 Households in the control arm were offered a short educational session on IPV.

287 Study arms were compared for time to MA detection (log-rank te

288 Differences between study arms were modeled using multivariable logistic regressio

289 Sham arms were pooled for analysis.

290 atients, an equal number of eyes (19 in each arm) were treated with standard-fluence and reduced-flue

291 or investigating motor control of the entire arm, which may aid the future development of soft roboti

292 erquartile range 17-62) in the ciprofloxacin arm, which was not significantly different (adjusted haz

293 onor genes and located away from chromosomal arms, which suggests a link between capture and gene mov

294 and solid cancers initially gain chromosome arms, while only solid cancers subsequently preferential

295 2 overexpression leads to an accumulation of Arm with GM130 Golgi marker in Klp64D knockdown.

296 Patients in the placebo arm with PAD versus those without tended to have higher

297 contrasts and only comparing multicomponent arms with LNS groups and comparison groups that containe

298 d phase 2 study in 90 patients (45 per study arm) with aggressive HIV-NHLs, using dose-adjusted EPOCH

299 Statistical analysis employed a 2 (Treatment Arm) X 3 (Time of Assessment) mixed-method analysis of v

300 l attenuation of transcription on chromosome arms, yet how the cell regulates nuclear and chromatin-a